This study is looking at how safe and effective a combination of two drugs, cabozantinib and high-dose ifosfamide, is for children and adults (ages 5 to 40) with sarcomas that have come back or are not responding to other treatments (relapsed/refractory sarcomas). Cabozantinib is a targeted therapy that works by blocking certain proteins called tyrosine kinases, including MET and VEGFR2, which can help tumors grow. The study aims to find the highest safe dose of cabozantinib when given with ifosfamide. You could be eligible if you have a confirmed diagnosis of any sarcoma. The study is currently recruiting about 30 participants.

Study design

This study is an interventional trial, meaning participants will receive a specific treatment. It plans to enroll about 30 participants.

What's involved

Participants will receive cabozantinib with high-dose ifosfamide for 5 cycles. If still on study, they will continue with cabozantinib alone for up to 12 total cycles.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, maximum tolerated dose, is measured approximately 1 year after the phase 1 cohort is complete.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.